Molecular Common Stock Shares Outstanding from 2010 to 2024
| MOLN Stock | USD 3.78 0.09 2.33% |
Common Stock Shares Outstanding | First Reported 2013-03-31 | Previous Quarter 32.9 M | Current Value 32.9 M | Quarterly Volatility 6.1 M |
Check Molecular Partners financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Molecular main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Interest Expense of 46.5 K or Selling General Administrative of 12.2 M, as well as many exotic indicators such as Price To Sales Ratio of 18.47, Dividend Yield of 0.0 or PTB Ratio of 0.62. Molecular financial statements analysis is a perfect complement when working with Molecular Partners Valuation or Volatility modules.
Molecular | Common Stock Shares Outstanding |
Latest Molecular Partners' Common Stock Shares Outstanding Growth Pattern
Below is the plot of the Common Stock Shares Outstanding of Molecular Partners AG over the last few years. It is the total number of shares of a company's common stock that are currently owned by all its shareholders. Molecular Partners' Common Stock Shares Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Molecular Partners' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Shares Outstanding | 10 Years Trend |
|
Common Stock Shares Outstanding |
| Timeline |
Molecular Common Stock Shares Outstanding Regression Statistics
| Arithmetic Mean | 22,981,296 | |
| Geometric Mean | 22,430,622 | |
| Coefficient Of Variation | 23.72 | |
| Mean Deviation | 4,421,207 | |
| Median | 20,861,797 | |
| Standard Deviation | 5,450,018 | |
| Sample Variance | 29.7T | |
| Range | 18M | |
| R-Value | 0.80 | |
| Mean Square Error | 11.4T | |
| R-Squared | 0.64 | |
| Significance | 0.0003 | |
| Slope | 978,667 | |
| Total Sum of Squares | 415.8T |
Molecular Common Stock Shares Outstanding History
About Molecular Partners Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Molecular Partners income statement, its balance sheet, and the statement of cash flows. Molecular Partners investors use historical funamental indicators, such as Molecular Partners's Common Stock Shares Outstanding, to determine how well the company is positioned to perform in the future. Although Molecular Partners investors may use each financial statement separately, they are all related. The changes in Molecular Partners's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Molecular Partners's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Molecular Partners Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Molecular Partners. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 32.8 M | 26 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Molecular Partners Correlation against competitors. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Molecular Stock analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Molecular Partners' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 0.215 | Quarterly Revenue Growth (0.62) | Return On Assets (0.17) | Return On Equity (0.30) |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.